Jump to contentJump to search

Previous 2019 Düsseldorf-Jülich Symposium


12 November 2019

09:00 Registration
Chair: Dieter Willbold, Heinrich Heine University Düsseldorf, Forschungszentrum Jülich, Germany

Welcome addresses

Anja Steinbeck, President, Heinrich Heine University Düsseldorf, Germany

Sebastian M. Schmidt, Member of the Board of Directors for Scientific Division I, Forschungszentrum Jülich GmbH, Germany

Michael Lorrain, Chairman Alzheimer Forschung Initiative e.V., Düsseldorf, Germany

Session I: Amyloids and Aggregation
Chairs: Janine Kutzsche, Forschungszentrum Jülich, Germany
Wolfgang Hoyer, Heinrich Heine University Düsseldorf, Germany

Characterization of the novel APP "Uppsala" mutation – causing an early onset form of Alzheimer’s disease,

Martin Ingelsson, Department of Public Health and Caring Sciences, Geriatrics, Uppsala University, Sweden

10:35 Coffee break

Post-translational modifications of amyloid beta peptides in distinct aggregation pathways and the progression of Alzheimer's disease,

Jochen Walter, Department of Neurology, University of Bonn, Germany


Direct elimination of Aβ oligomers by the orally available clinical stage anti-prionic compound PRI-002 reverses cognition deficits and decelerates neurodegeneration in AD animal models,

Dieter Willbold, Institut für Physikalische Biologie, Heinrich Heine University Düsseldorf and ICS-6: Structural Biochemistry, Forschungszentrum Jülich, Germany


Environmental pollutants induce neurodegeneration via the gut-neural axis,

Annette Piechulek, IUF - Leibniz Research Institute of Environmental Medicine at Heinrich-Heine-University Düsseldorf,  Germany
Talk by early career scientist

13:00 Lunch break

Seeded protein aggregation as the defining mechanism in Alzheimer’s disease,

Lary C. Walker, Department of Neurology and Yerkes Center, Emory University, Atlanta, USA


Conformers of assembled tau,

Michel Goedert, MRC Laboratory of Molecular Biology, Cambridge, UK

15:30 Coffee break

Protein fibrils in infectious and aggregation diseases,

Meytal Landau, Department of Biology, Technion - Israel Institute of Technology, Haifa, Israel


N-terminal truncated Abeta4-42 is a substrate for neprilysin degradation in vitro and in vivo,
Silvia Zampar, Department of Psychiatry and Psychotherapy, University Medical Center, Georg-August University, Göttingen, Germany

Talk by early career scientist

17:10 Break
Public Science Lecture jointly organized with Alzheimer Forschung Initiative e.V. (AFI)
  Admission to Public Science Lecture

Neue Wirkstoffe gegen Alzheimer – Ist Heilung in Sicht?

Oliver Peters, Charité Universitätsmedizin Berlin, Germany


13 November 2019

Session II: Prions and Biomarkers
Chair: Oliver Bannach, Forschungszentrum Jülich, Germany

Biomarkers for neurodegenerative disease gleaned through brain-derived blood exosomes,

Gal Bitan, Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, USA

10:20 Is kallikrein-related peptidase 6 in cerebrospinal fluid a suitable biomarker for Alzheimer's pathology? - evidence for its pathophysical involvement,
Oliver Goldhardt, Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar, Technical University of Munich, School of Medicine, Munich, Germany
Talk by early career scientist
10:40 Coffee break

Aggregation kinetics to study biological strain diversity in neurodegenerative diseases,

Inga Zerr, Clinical Dementia Center, Dpt. of Neurology, University Medical School, Georg-August University, Göttingen and German Center for Neurodegenerative Diseases, Germany


Towards translation in frontotemporal dementia and Parkinson's disease,

Alice S. Chen-Plotkin, Parker Family Associate Professor of Neurology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, USA

12:40 Lunch break
Session III: Aggregation and Homeostasis
Chair: Inga Kadish, University of Alabama at Birmingham, AL, USA

A role of linear ubiquitination in protein quality control: Implications for neurodegenerative diseases,

Konstanze F. Winklhofer, Molecular Cell Biology, Ruhr-University Bochum, Germany



The intrinsically disordered N-terminal domain of the prion protein as an integrator of neuroprotective and neurotoxic signaling,

Jörg Tatzelt, Department Biochemistry of Neurodegenerative Diseases, Ruhr-University Bochum, Germany

15:10 Organotypic hippocampal slice cultures as a model system to study the role of glial cells and neuroinflammation in Alzheimer's disease,
Natascha Vidovic, Philipps University Marburg and University Hospital Essen, Germany
Talk by early career scientist
15.30 Coffee break

Loss of protein quality control in sporadic Alzheimer's disease – does it start with altered ubiquitin signaling?

Michael H. Glickman, Technion – Israel Institute of Technology, Haifa, Israel and
Fred van Leeuwen, Maastricht University, Maastricht, the Netherlands


Autophagy pathways in stress response and neurodegenerative disease,

Christian Behl, University Medical Center Mainz, Johannes-Gutenberg University Mainz, Germany


AFI Funding Opportunities,

Jochen Walter, University of Bonn, Germany

Poster Session
18:00 Poster session with guided poster tours and finger food buffet


14 November 2019

Session IV: Prions and Fibrils
Chair: Erdem Tamgüney, Heinrich Heine University Düsseldorf , Germany

Translating structural biology into disease prophylaxis: Rationally designed, structure-based vaccines for Prion disease and other neurodegenerative diseases?

Holger Wille, Centre for Prions and Protein Folding Diseases & Department of Biochemistry, University of Alberta, Edmonton, Canada


Axonal pathology at amyloid plaques and its relevance for preventive therapeutical approaches,

Jochen Herms, German Center for Neurodegenerative Diseases and Center for Neuropathology, Ludwig-Maximilians-Universität München, Germany

11:10 pH-induced structural changes in Alzheimer's amyloid fibril Aβ(1-42),
Nina Becker, ICS-6: Structural Biochemistry, Forschungszentrum Jülich and Institut für Physikalische Biologie, Heinrich Heine University Düsseldorf, Germany
Talk by early career scientist
11:30 Lunch break

Structure-activity relationship by kinetics for drug discovery in protein misfolding diseases,

Michele Vendruscolo, Department of Chemistry, University of Cambridge, UK


Structures of Amyloids: From the origin to the end of life,

Roland Riek, Biological Nuclear Magnetic Resonance, Laboratory of Physical Chemistry, Department of Chemistry and Applied Sciences, ETH Zürich, Switzerland

13:40 Coffee break
Panel Discussion

Panel discussion

  1. Do we really know what causes AD?
  2. New treatments for AD, is Aβ still viable? Do we need to focus on Tau? Or something else altogether?
  3. Do Aβ and/or Tau assemblies behave prion-like?
Panel members:
Christian Behl, Michel Goedert, Meytal Landau and Lary Walker

The panel discussion will be moderated by Thomas van Groen
Poster Prize Award
15:00 Poster prizes
sponsored by Alzheimer Forschung Initiative e.V.

Closing remarks,

Thomas van Groen and Dieter Willbold, organizing committee





The Symposium is generously supported by Alzheimer Forschung Initivative e.V. and Joachim Herz Stiftung.

Responsible for the content: